Stock SLRN ACELYRIN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Acelyrin, Inc.

Equities

SLRN

US00445A1007

Market Closed - Nasdaq
Other stock markets
 01:30:00 01/06/2024 am IST 		5-day change 1st Jan Change
4.12 USD +1.73% Intraday chart for Acelyrin, Inc. -0.24% -44.77%
22/05 HC Wainwright Adjusts Price Target on ACELYRIN to $18 From $16, Maintains Buy Rating MT
14/05 Acelyrin, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
GL
ACELYRIN, INC. Announces Leadership Transition
GL
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
GL
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
GL
Affibody publishes Annual Report 2023
AQ
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
GL
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
AQ
Acelyrin : Corporate Presentation
PU
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
GL
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
AQ
Affibody’s Partner ACELYRIN Announces Positive Top-line Results for Izokibep in Psoriatic Arthritis and Long-Term Clinical Benefits in Hidradenitis Suppurativa
AQ
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
GL
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
AQ
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
GL
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
GL
Levi & Korsinsky Notifies Acelyrin, Inc.(SLRN) Investors of a Class Action Lawsuit and Upcoming Deadline
PR
FINAL SLRN DEADLINE: Bronstein, Gewirtz & Grossman LLC Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
PR
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acelyrin, Inc. of Class Action Lawsuit and Upcoming Deadline - SLRN
PR
SLRN Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Acelyrin, Inc. (SLRN) of Deadline in Securities Fraud Class Action Lawsuit
PR
The Gross Law Firm Notifies Shareholders of Acelyrin, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2024 - (NASDAQ: SLRN)
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SLRN Stock
  4. News Acelyrin, Inc.
  5. Press Releases